The group’s principle activity is to redefine heart failure therapy by developing devices that prevent or reverse the underlying disease progression of heart failure. The group’s products include Cancion(R) System and Exeleras(R) System. The group operates from United States.
Executive Information
Name
Title
Email
Kenneth Charhut
Dir., CEO, Pres.
N/A
Irene Parker
VP - Global QA, Regulatory Affairs, Compliance Officer
